Amgen

Amgen (amgn) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $207.63, marking a -0.77% move from the previous day. This change lagged the S&P 500's 0.48% gain on the day.Heading into today, shares of the world's largest biotech drugmaker had lost 2.05%...

Read More →

How To Find Stocks On Sale In 2021

(1:00) - Small Cap Stocks Near 52 Week Lows: Stock Screener(6:35) - Finding Cheap Stocks For Your Portfolio: Tracey’s Top Picks(17:20) - Episode Roundup: T, VZ, AMGN, ZM, POSH, REAL,...

Read More →

Amgen (amgn) Reports New Data From Lumakras Combo Study

Amgen AMGN announced new data from two combination arms of the phase Ib CodeBreaK 101 study. The CodeBreaK 101 study is evaluating Lumakras (sotorasib) in different combination regimens to treat KRAS G12C-mutated cancers.One arm evaluated...
Related topics: Medical Research, Cancer, Oncology

Read More →

The Zacks Analyst Blog Highlights: Tesla, Jpmorgan, Oracle, Amgen And Lam Research

For Immediate ReleaseChicago, IL – September 29, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the...
Related topics: Tesla, J.P. Morgan Chase & Co., Oracle (business)

Read More →

Amgen (amgn) Repatha Gets Fda Nod For Expanded Use In Kids

Amgen AMGN announced that the FDA has approved its PCSK9 inhibitor, Repatha for different forms of familial hypercholesterolemia (FH) in pediatric patients.The first approval is for Repatha as an adjunct to diet and other low-density lipoprotein...
Related topics: Food And Drug Administration, Diet

Read More →

Questions About Pharma Pricing And Marketing

In 2017, Allergan CEO Brent Saunders promised to reign in drug price hikes, and other Pharma companies followed suit. In 2021, it looks like all bets are off. In August, Amgen raised the price of its psoriasis med Otezla by 2.4 percent after raising...
Related topics: Marketing, Psoriasis

Read More →

These Promising Clinical Results Could Be Huge For Amgen Investors

Amgen (NASDAQ: AMGN) recently shared data from its Phase 3 trial of tezepelumab, which it is developing in collaboration with AstraZeneca (NASDAQ: AZN). Tezepelumab was shown to be very effective in reducing "exacerbations and helping lung function...
Related topics: Nasdaq, US Equity Markets, Astrazeneca

Read More →

Tuesday’s Top Analyst Upgrades And Downgrades: Amgen, Cirrus Logic, Johnson & Johnson, Lam...

Tuesday’s top analyst upgrades and downgrades included Amgen, Cirrus Logic, Hain Celestial, Johnson & Johnson, Lam Research, Merck, Spotify Technology and Vertex Pharmaceuticals.
Related topics: Merck & Co, Spotify, Vertex Pharmaceuticals

Read More →

Amgen (amgn) Outpaces Stock Market Gains: What You Should Know

Amgen (AMGN) closed at $225.96 in the latest trading session, marking a +1.17% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.28%.Coming into today, shares of the world's largest biotech drugmaker had lost 2.17% in the...

Read More →

Amgen (amgn) Down 2.2% Since Last Earnings Report: Can It Rebound?

A month has gone by since the last earnings report for Amgen (AMGN). Shares have lost about 2.2% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Amgen due for a...

Read More →

Why Amgen Is Down Nearly 7% Today

Amgen (NASDAQ: AMGN) shares were trading 6.8% lower late Wednesday following a second-quarter earnings beat that was marred by lowered full-year guidance.The biopharma outfit turned $6.5 billion worth of sales into per-share earnings of $4.38 for...
Related topics: Nasdaq, US Equity Markets, Earnings Per Share

Read More →

Healthcare Stock Sell-off Keeps The Dow Jones From Reaching Record Levels

Shares of pharmaceutical giant Merck (NYSE: MRK) fell almost 2% after reporting earnings, joined by Amgen (NASDAQ: AMGN) and Walgreens Boots Alliance in a handful of Dow Jones Industrial Average (DJINDICES: ^DJI) stocks in the red on July 29....
Related topics: Merck & Co, US Equity Markets, Nasdaq

Read More →

Analysts Estimate Amgen (amgn) To Report A Decline In Earnings: What To Look Out For

Amgen (AMGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2021. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how...

Read More →

Amgen (amgn)/astrazeneca's Asthma Drug Gets Fda Priority Tag

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report AstraZeneca PLC...
Related topics: Astrazeneca

Read More →

Labcorp (lh) Expands Testing Portfolio With The Launch Of Cdx

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report Amgen...

Read More →

The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen And Sony Group

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Visa Inc. (V): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock...
Related topics: Google, Google (GOOG)

Read More →

Should You Invest In The Invesco Dynamic Biotechnology & Genome Etf (pbe)?

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Invesco Dynamic Biotechnology & Genome ETF (PBE): ETF Research Reports Amgen Inc....
Related topics: Invesco

Read More →

Should You Buy Biotech Etfs Now?

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis...

Read More →

Amgen Inc (amgn): Price Now Near $240.18; Daily Chart Shows Downtrend On 50 Day Basis

The Hourly View for AMGN At the moment, AMGN (Get Ratings)’s price is down $-1.12 (-0.46%) from the hour prior. This is the 2nd hour in a row AMGN has seen its price head down. As for the trend on the hourly timeframe, we see the clearest...

Read More →

This Is Why Amgen's New Cancer Drug Could Be Huge

Biotechnology stocks are famous for dramatic price movements but smart investors have been eager to scoop up shares of Amgen (NASDAQ: AMGN) for a different reason. Despite a development pipeline that few analysts would describe as prolific,...
Related topics: Nasdaq, US Equity Markets

Read More →
What is noozilla?
Noozilla is an independent news aggregation service with a categorization engine that categorizes millions of news stories by subject.